JonathanRStrosbergMD

Professor, Moffitt Cancer Center, Department of GI Oncology

Overview of Dr. Strosberg

Dr. Jonathan Strosberg is an oncologist at the Moffitt Cancer Center in Tampa, FL, with specialized expertise in neuroendocrine cancers. Dr. Strosberg has contributed to the field through multiple publications on neuroendocrine tumors, with his research being featured in esteemed journals such as The New England Journal of Medicine. Additionally, he has played significant roles in various clinical trials focusing on innovative treatments for neuroendocrine tumors.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(763) 703-1474

Education & Training

University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1999 - 2002
Weill Cornell MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2003 - 2027
DC State Medical License 2002 - 2004
MT State Medical License 2003 - 2004
VA State Medical License 2000 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) Start of enrollment: 2003 Oct 01
Terminated
Phase 2
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Start of enrollment: 2006 Nov 01
Completed
Phase 2
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors Start of enrollment: 2007 Aug 01
Terminated
Phase 2
RO4929097 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2010 May 01
Completed
Phase 2
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Start of enrollment: 2011 Feb 01
Completed
Phase 2
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) Start of enrollment: 2011 Aug 01
Completed
Phase 1
A Study of Axitinib in Advanced Carcinoid Tumors Start of enrollment: 2011 Oct 25
Completed
Phase 2
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06
Completed
Phase 3
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
ACTIVE_NOT_RECRUITING
PHASE2
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 Jun 18
Completed
Phase 2
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Start of enrollment: 2015 Oct 09
Completed
Phase 2
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors Start of enrollment: 2017 Jan 09
Completed
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Completed
Phase 2
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors Start of enrollment: 2017 Dec 15
COMPLETED
PHASE2
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Start of enrollment: 2020 Jan 08
ACTIVE_NOT_RECRUITING
PHASE3
Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression Start of enrollment: 2019 Nov 13
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
RECRUITING
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC).
Halfdan Sorbye, Grace Kong, Simona Grozinsky-Glasberg, Jonathan Strosberg
Journal of Neuroendocrinology. 2025-03-01
8 citations
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Jennifer A Chan, Susan Geyer, Tyler Zemla, Michael V Knopp, Spencer Behr
The New England Journal of Medicine. 2025-02-13
The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumors.
Taymeyah Al-Toubah, Jonathan Strosberg
Journal of Neuroendocrinology. 2025-01-24

Lectures

Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
2019 ASCO Annual Meeting - 6/1/2019
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Role of Nuclear Medicine in Neuroendocrine Cancers
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Other

Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-10-31
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-11-21
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-11-21
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2013-02-05
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2013-01-14
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-12-10
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2012-11-09
Gastroenteropancreatic Neuroendocrine Tumors
Jonathan Strosberg, MD, CA: A Cancer Journal for Clinicians
https://www.doximity.com/articles/3d2e974e-5c9f-4cd1-9c71-10c734c384cc
UpToDate, Wolters Kluwer Health - 2013-02-28
Join now to see all

Press Mentions

ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-Edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 ConferenceMarch 6th, 2025
'Clinically Meaningful' Survival Gain in Neuroendocrine TumorsJuly 1st, 2021
Strosberg Discusses Lutathera Approval, Remaining Challenges in NETsFebruary 28th, 2018
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access Choice PPO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
Anthem Blue Preferred Select
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment